Stock Forecast

  ImmunoPrecise Antibodies Ltd. ( IPA) Stock. Should you Buy or Sell?    $ 5.65

0.61 (9.74 %)



ImmunoPrecise Antibodies Ltd. Analysis

Updated on 10-09-2022
Symbol IPA
Price $5.65
Beta 0.126
Volume Avg. $15.09 thousand
Market Cap $148.08 M
52 Week Range $3.51 - $7.16


ImmunoPrecise Antibodies Ltd. opened the day at $5.65 which is +'9.74 % on yesterday's close. ImmunoPrecise Antibodies Ltd. has a 52 week high of $7.16 and 52 week low of $3.51, which is a difference of $3.65. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $148.08 M and total net profit is $19364000 which means the company is trading at 7.65 times profit to market capitalization. Theoretically, if you were to buy ImmunoPrecise Antibodies Ltd. for $148.08 M, it would take 15 years to get your money back. ImmunoPrecise Antibodies Ltd. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




ImmunoPrecise Antibodies Ltd. Stock Forecast - Is ImmunoPrecise Antibodies Ltd. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -8.278
Dividend Yiel 0.000
Net Profit Margin -0.863


Valuing ImmunoPrecise Antibodies Ltd.


Price Book Value Ratio 1.837 Price To Book Ratio 1.837
Price To Sales Ratio 7.143 Price Earnings Ratio -8.278


How liquid is ImmunoPrecise Antibodies Ltd.


Current Ratio 4.045
Quick Ratio 3.603


Debt


Debt Ratio 0.195 Debt Equity Ratio 0.242
Long Term Debt To Capitalization 0.005 Total Debt To Capitalization 0.033



Latest news about ImmunoPrecise Antibodies Ltd.


IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise manag

Date : 08/09/2022

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on Friday, July 29, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise man

Date : 26/07/2022

ImmunoPrecise Antibodies Ltd. (IPA) CEO Jennifer Bath on Q3 2022 Results - Earnings Call Transcript

ImmunoPrecise Antibodies Ltd. (IPA) CEO Jennifer Bath on Q3 2022 Results - Earnings Call Transcript

Date : 16/03/2022

ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced today announced that it will host a conference call to discuss its financial results and recent business highlights for third quarter fiscal year 2022, on Wednesday, March 16th, 2022, at 10:30 a.m. ET. The financial results will be issued in a press release prior to the call.

Date : 08/03/2022

ImmunoPrecise's COVID-19 Antibody Cocktail Shows Neutralization Activity Against Omicron

Immunoprecise Antibodies Ltd IPA has released preclinical data for the PolyTope TATX-03 COVID-19 antibody cocktail. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Date : 31/01/2022





About ImmunoPrecise Antibodies Ltd.


CEO :
Sector : Healthcare
Industry : Biotechnology

Website : https://www.ipatherapeutics.com

Exchange : NASDAQ Global Market

Description :

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.


My Newsletter

Sign Up For Updates & Newsletters